Since the presence of KRAS mutations is used as the standard for identifying ctDNA in patients with pancreatic cancer, we compared the ability of our method to detect KRAS mutations to that of conventional deep sequencing. The gene discussed is KRAS; the disease is pancreatic neoplasm.